» Articles » PMID: 22396581

Platelet Function Measurement-based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-treated Patients Undergoing Coronary Artery Bypass Graft Surgery: the Timing Based on Platelet Function Strategy to Reduce Clopidogrel-associated...

Overview
Date 2012 Mar 8
PMID 22396581
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Aspirin and clopidogrel therapy is associated with a variable bleeding risk in patients undergoing coronary artery bypass graft surgery (CABG). We evaluated the role of platelet function testing in clopidogrel-treated patients undergoing CABG.

Methods And Results: One hundred eighty patients on background aspirin with/without clopidogrel therapy undergoing elective first time isolated on-pump CABG were enrolled in a prospective single-center, nonrandomized, unblinded investigation (Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG [TARGET-CABG] study) between September 2008 and January 2011. Clopidogrel responsiveness (ADP-induced platelet-fibrin clot strength [MA(ADP)]) was determined by thrombelastography; CABG was done within 1 day, 3-5 days, and >5 days in patients with an MA(ADP) >50 mm, 35-50 mm, and <35 mm, respectively. The primary end point was 24-hour chest tube drainage and key secondary end point was total number of transfused red blood cells. Equivalence was defined as ≤25% difference between groups. ANCOVA was used to adjust for confounders. Mean 24-hour chest tube drainage in clopidogrel-treated patients was 93% (95% confidence interval, 81-107%) of the amount observed in clopidogrel-naive patients, and the total amount of red blood cells transfused did not differ between groups (1.80 U versus 2.08 U, respectively, P=0.540). The total waiting period in clopidogrel-treated patients was 233 days (mean, 2.7 days per patient).

Conclusions: A strategy based on preoperative platelet function testing to determine the timing of CABG in clopidogrel-treated patients was associated with the same amount of bleeding observed in clopidogrel-naive patients and ≈50% shorter waiting time than recommended in the current guidelines.

Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00857155.

Citing Articles

Early vs Delayed Bypass Surgery in Patients With Acute Coronary Syndrome Receiving Ticagrelor: The RAPID CABG Randomized Open-Label Noninferiority Trial.

So D, Wells G, Lordkipanidze M, Chong A, Ruel M, Perrault L JAMA Surg. 2025; .

PMID: 39969871 PMC: 11840690. DOI: 10.1001/jamasurg.2024.7066.


Antiplatelet Therapy in Low-Platelet-Count Patients After Percutaneous Coronary Intervention for Acute Coronary Syndromes.

Paciullo F, Gresele P J Clin Med. 2025; 14(3).

PMID: 39941509 PMC: 11818633. DOI: 10.3390/jcm14030838.


Methodological Considerations for Studies Evaluating Bleeding Prediction Using Hemostatic Point-of-Care Tests in Cardiac Surgery.

Petricevic M, Goerlinger K, Milojevic M, Petricevic M J Clin Med. 2024; 13(22).

PMID: 39597881 PMC: 11595064. DOI: 10.3390/jcm13226737.


Thromboelastography with Platelet Mapping to Optimize Surgical Timing in Coronary Artery Bypass Grafting Patients on P2Y12 Receptor Blockers Therapy.

Dambruoso P, Raimondo P, Massaro F, DAniello M, Di pinto G Braz J Cardiovasc Surg. 2024; e20230292(e20230292).

PMID: 39471263 PMC: 11495379. DOI: 10.21470/1678-9741-2023-0292.


How to undertake procedures while on antiplatelet agents: a hematologist's view.

Swan D, Turner R, Douketis J, Thachil J Res Pract Thromb Haemost. 2024; 8(6):102539.

PMID: 39318772 PMC: 11419924. DOI: 10.1016/j.rpth.2024.102539.